Abstract
In recent clinical trials, engineered CAR T cells have yielded response rates as high as 90% in patients with leukemia. Now, scientists are working to get this therapy to market and possibly expand its use into solid tumors.
©2015 American Association for Cancer Research.
MeSH terms
-
Humans
-
Immunotherapy*
-
Neoplasms / immunology*
-
Neoplasms / therapy*
-
Receptors, Antigen, T-Cell / genetics*
-
Receptors, Antigen, T-Cell / metabolism
-
Recombinant Fusion Proteins / genetics*
-
Recombinant Fusion Proteins / metabolism
-
T-Lymphocytes / immunology*
-
T-Lymphocytes / metabolism*
Substances
-
Receptors, Antigen, T-Cell
-
Recombinant Fusion Proteins